Communiqués Corbus Pharmaceuticals Holdings, Inc.

Actions

CRBP

US21833P3010

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 06/08/2026			Varia. 5j.	Varia. 1 janv.
9,740 ^USD	+1,78%		+7,62%	+19,66%

06/08	Corbus Pharmaceuticals Holdings, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
04/08	Corbus Pharmaceuticals annonce la dernière visite du dernier patient de l'étude Canyon-1 sur le CRB-913 dans le traitement de l'obésité	CI

Communiqués

06/08	Corbus Pharmaceuticals: Q2 Earnings Snapshot	AQ
06/08	Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update	AQ
04/08	Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity	AQ
28/07	Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer	AQ
06/07	Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer	AQ
26/05	Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers	AQ
21/05	Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call	AQ
14/05	Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors	AQ
13/05	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences	AQ
12/05	Corbus Pharmaceuticals: Q1 Earnings Snapshot	AQ
12/05	Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update	AQ
05/05	Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026	AQ
22/04	Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701	AQ
14/04	Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity	AQ
18/03	Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit	AQ
09/03	Corbus Pharmaceuticals: Q4 Earnings Snapshot	AQ
09/03	Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update	AQ
12/02	Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference	AQ
05/01	Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
11/12	Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss	AQ
10/12	Corbus Pharmaceuticals : to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025	PU
10/12	Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025	AQ
12/11	Corbus Pharmaceuticals: Q3 Earnings Snapshot	AQ
12/11	Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update	AQ
06/11	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences	AQ